Source: http://www.patentsencyclopedia.com/app/20110311481
Timestamp: 2019-05-22 09:29:08
Document Index: 755169137

Matched Legal Cases: ['§120', '§119', 'Application No. 60', '§120', '§120', '§119', '§120', '§119', 'Application No. 60']

Inventors: Anil Gulati (Naperville, IL, US) Guru Reddy (Irvine, CA, US) Guru Reddy (Irvine, CA, US) Luigi Lenaz (Newtown, PA, US)
Assignees: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS SPECTRUM PHARMACEUTICALS, INC.
Patent application number: 20110311481
1. An article of manufacture comprising: (a) a packaged composition comprising an IRL-1620, and; (b) an insert providing instructions for the administration of (a) for the treatment of an ovarian tumor in a mammal; and (c) a container for (a) and (b).
2. The article of manufacture according to claim 1, wherein said article of manufacture further comprises (d) a chemotherapeutic agent, said instructions provide for administration of (a) and (d) and said container (c) is for (a), (b) and (d).
3. The article of manufacture according to claim 2, wherein said chemotherapeutic agent is selected from the group consisting of adriamycin, camptothecin, carboplatin, cisplatin, daunorubicin, doxorubicin, alpha interferon, beta interferon, gamma interferon, interleukin 2, innotecan, docetaxel, paclitaxel, topotecan, and mixtures thereof.
4. The article of manufacture according to claim 2, wherein said chemotherapeutic agent is paclitaxel.
5. The article of manufacture according to claim 2, wherein when said instructions are followed, said IRL-1620 selectively increases blood supply to said ovarian tumor thus increasing the delivery of said chemotherapeutic agent to said ovarian tumor.
6. The article of manufacture according to claim 3, wherein the pharmacokinetics of said chemotherapeutic agent are not affected by said IRL-1620.
7. The article of manufacture according to claim 3, wherein said IRL-1620 enhances the efficacy of said chemotherapeutic agent.
8. An article of manufacture comprising: (a) a packaged composition comprising an IRL-1620; (b) a packaged composition comprising a chemotherapeutic agent; (c) an insert providing instructions for a simultaneous or sequential administration of (a) and (b) to treat an ovarian tumor in a mammal; and (d) a container for (a), (b), and (c)
9. The article of manufacture according to claim 8, wherein said chemotherapeutic agent is selected from the group consisting of adriamycin, camptothecin, carboplatin, cisplatin, daunorubicin, doxorubicin, alpha interferon, beta interferon, gamma interferon, interleukin 2, irinotecan, docetaxel, paclitaxel, topotecan, and mixtures thereof.
10. The article of manufacture according to claim 8, wherein said chemotherapeutic agent is paclitaxel.
[0001] This patent application is a continuation and claims the benefit of priority pursuant to 35 U.S.C. §120 to U.S. patent application Ser. No. 12/101,008, filed Apr. 10, 2008, (which claims the benefit of priority pursuant to 35 U.S.C. §119(e) to U.S. Provisional Patent Application No. 60/911,773, filed on Apr. 13, 2007), a continuation that claims priority pursuant to 35 U.S.C. §120 to U.S. patent application Ser. No. 11/461,961 filed Aug. 2, 2006, now abandoned, a continuation-in-part that claims priority pursuant to 35 U.S.C. §120 to U.S. patent application Ser. No. 11/360,236, filed Feb. 22, 2006, (which claims the benefit of priority pursuant to 35 U.S.C. §119(e) to U.S. Provisional Patent Application Nos. 60/655,656; 60/655,654; and 60/655,643, all filed on Feb. 22, 2005), a continuation-in-part that claims priority pursuant to 35 U.S.C. §120 to U.S. patent application Ser. No. 10/691,915, filed Oct. 23, 2003, now abandoned, a patent application that claims the benefit of priority pursuant to 35 U.S.C. §119(e) to U.S. Provisional Patent Application No. 60/420,960, filed Oct. 24, 2002; each of which is hereby incorporated by reference in its entirety.
[0025] ETB agonists useful in accordance with the present invention include, without limitation, ET-1, ET-2, ET-3, BQ3020, IRL1620 (N-suc-[Glu9, Ala11,15]ET-1 (8-21)), sarafotoxin 56c, [Ala1,3,11,15]ET-1, and combinations thereof. [Ala1,3,11,15]ET-1 is a linear analog of ET-1 in which the disulfide bridges have been removed by substitution of Ala for Cys residues. Saeki et al., Biochem Biophys Res Commun, 179:286 (1991). BQ3020 and IRL1620 are truncated linear synthetic analogs of ET-1 and are the most widely used selective synthetic agonists. IRL-1620 is a linear ET-analog whose structure is based on the carboxy terminal end of ET-1 and has 120,000 fold selectivity for the ETB receptors. Okada & Nishikibe, Cardiovasc Drug Rev, 20:53 (2002); Douglas et al., Br J Pharmacol, 114:1529 (1995). IRL-1620 is a highly selective and potent ETB agonist, with evidence being reported of its selectivity for the ETB1 receptor subtype in preference over the ETB2 subtype. Brooks et al., J Cardiovasc Pharmacol, 26 Suppl 3:S322 (1995).
2010-01-07 Method and composition for the treatment of skin conditions
2009-12-31 Use of an anti-cd151 antibody in the treatment of cancer
2009-12-31 Product and composition for alleviating post-menstrual symptoms